Cargando…

The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants

Vaccination against SARS-CoV-2 protects from infection and improves clinical outcomes in breakthrough infections, likely reflecting residual vaccine-elicited immunity and recall of immunological memory. Here, we define the early kinetics of spike-specific humoral and cellular immunity after vaccinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koutsakos, Marios, Lee, Wen Shi, Reynaldi, Arnold, Tan, Hyon-Xhi, Gare, Grace, Kinsella, Paul, Liew, Kwee Chin, Taiaroa, George, Williamson, Deborah A., Kent, Helen E., Stadler, Eva, Cromer, Deborah, Khoury, David S., Wheatley, Adam K., Juno, Jennifer A., Davenport, Miles P., Kent, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135796/ https://www.ncbi.nlm.nih.gov/pubmed/35690062 http://dx.doi.org/10.1016/j.immuni.2022.05.018

Ejemplares similares

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
por: Lee, Wen Shi, et al.
Publicado: (2023)

SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses
por: Koutsakos, Marios, et al.
Publicado: (2023)

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
por: Cromer, Deborah, et al.
Publicado: (2021)

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
por: Kent, Stephen J., et al.
Publicado: (2022)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
por: Cromer, Deborah, et al.
Publicado: (2022)

Immune imprinting and SARS-CoV-2 vaccine design
por: Wheatley, Adam K., et al.
Publicado: (2021)

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
por: Khoury, David S., et al.
Publicado: (2020)

Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
por: Selva, Kevin J., et al.
Publicado: (2023)

Decay of Fc-dependent antibody functions after mild to moderate COVID-19
por: Lee, Wen Shi, et al.
Publicado: (2021)

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
por: Cromer, Deborah, et al.
Publicado: (2023)

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
por: Wheatley, Adam K., et al.
Publicado: (2021)

Inducible Bronchus-Associated Lymphoid Tissues (iBALT) Serve as Sites of B Cell Selection and Maturation Following Influenza Infection in Mice
por: Tan, Hyon-Xhi, et al.
Publicado: (2019)

Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
por: Liu, Yi, et al.
Publicado: (2019)

Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem
por: Jiang, Wenbo, et al.
Publicado: (2020)

Adaptive immunity to human coronaviruses is widespread but low in magnitude
por: Tan, Hyon‐Xhi, et al.
Publicado: (2021)

Influenza lineage extinction during the COVID-19 pandemic?
por: Koutsakos, Marios, et al.
Publicado: (2021)

Interplay of infection and vaccination in long-term protection from COVID-19
por: Tan, Hyon-Xhi, et al.
Publicado: (2022)

Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells
por: Jiang, Wenbo, et al.
Publicado: (2021)

Sequencing B cell receptors from ferrets (Mustela putorius furo)
por: Wong, Julius, et al.
Publicado: (2020)

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
por: Khoury, David S., et al.
Publicado: (2023)

Monoclonal antibody levels and protection from COVID-19
por: Stadler, Eva, et al.
Publicado: (2023)

Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
por: Pilapitiya, Devaki, et al.
Publicado: (2023)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Selva, Kevin J, et al.
Publicado: (2021)

Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
por: Lee, Wen Shi, et al.
Publicado: (2021)

SARS‐CoV‐2‐specific CD8(+) T‐cell responses and TCR signatures in the context of a prominent HLA‐A*24:02 allomorph
por: Rowntree, Louise C, et al.
Publicado: (2021)

Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem
por: Tan, Hyon-Xhi, et al.
Publicado: (2019)

Evidence for exposure dependent carriage of malaria parasites across the dry season: modelling analysis of longitudinal data
por: Stadler, Eva, et al.
Publicado: (2023)

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
por: Tan, Hyon-Xhi, et al.
Publicado: (2021)

Reduced erythrocyte susceptibility and increased host clearance of young parasites slows Plasmodium growth in a murine model of severe malaria
por: Khoury, David S., et al.
Publicado: (2015)

Where Have All the Parasites Gone? Modelling Early Malaria Parasite Sequestration Dynamics
por: Cromer, Deborah, et al.
Publicado: (2013)

Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection
por: D’Orso, Silvia, et al.
Publicado: (2023)

Suboptimal SARS-CoV-2−specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype
por: Habel, Jennifer R., et al.
Publicado: (2020)

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
por: Pinkevych, Mykola, et al.
Publicado: (2016)

A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library
por: Waugh, Caryll, et al.
Publicado: (2015)

Population heterogeneity in Plasmodium vivax relapse risk
por: Stadler, Eva, et al.
Publicado: (2022)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
por: Wheatley, Adam K., et al.
Publicado: (2021)

Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study
por: Anderson, Gary P., et al.
Publicado: (2023)

Does an Adolescent’s Accuracy of Recall Improve with a Second 24-h Dietary Recall?
por: Kerr, Deborah A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e99nup88ne35diq2k8q9dkank4